{"nctId":"NCT00781274","briefTitle":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy","startDateStruct":{"date":"2008-12"},"conditions":["Hepatitis C"],"count":32,"armGroups":[{"label":"MP-424","type":"EXPERIMENTAL","interventionNames":["Drug: MP-424","Drug: Ribavirin","Drug: Peginterferon Alfa-2b"]}],"interventions":[{"name":"MP-424","otherNames":["Telaprevir"]},{"name":"Ribavirin","otherNames":[]},{"name":"Peginterferon Alfa-2b","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Genotype 1, chronic hepatitis C\n* Non-responders (patient who did not respond to previous treatment)\n* Able and willing to follow contraception requirements\n\nExclusion Criteria:\n\n* Cirrhosis of the liver or hepatic failure\n* Hepatitis B surface antigen-positive or HIV antibodies-positive\n* History of, or concurrent hepatocellular carcinoma\n* History of, or concurrent depression, schizophrenia; or suicide attempt in the past\n* Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":32},"commonTop":["Anaemia","Pyrexia","Blood uric acid increased","Malaise","White blood cell count decreased"]}}}